Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial.

Blood pressure. Supplement Pub Date : 2003-05-01 DOI:10.1080/08038020310000087

Claudio Borghi, Maria Grazia Prandin, Ada Dormi, Ettore Ambrosioni

{"title":"Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial.","authors":"Claudio Borghi, Maria Grazia Prandin, Ada Dormi, Ettore Ambrosioni","doi":"10.1080/08038020310000087","DOIUrl":null,"url":null,"abstract":"<p><p>The objective of this 8-week open-label study was to compare the tolerability of lercanidipine, a dihydropyridine calcium-channel antagonist (CA), with that of other CAs in the treatment of hypertension. Subjects already taking amlodipine, felodipine, nifedipine gastrointestinal therapeutic system (GITS), or nitrendipine and experiencing CA-specific adverse effects (AEs) were switched to lercanidipine for 4 weeks and then rechallenged with their initial treatment for 4 weeks. Results showed that at comparable levels of BP, lercanidipine was associated with a significantly lower incidence of ankle edema, flushing, rash, headache and dizziness compared with other CAs (p < 0.001). After 4 weeks of lercanidipine, mean systolic blood pressure (SBP)/diastolic blood pressure (DBP) was 142.1/86.7 mmHg. After rechallenge with other CAs for 4 weeks, mean SBP/DBP was 141.1/86.7 mmHg. In this open-label study, lercanidipine compared with other CA seems to provide a significant improvement in tolerability with comparable antihypertensive effect.</p>","PeriodicalId":8974,"journal":{"name":"Blood pressure. Supplement","volume":"1 ","pages":"14-21"},"PeriodicalIF":0.0000,"publicationDate":"2003-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/08038020310000087","citationCount":"36","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood pressure. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/08038020310000087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 36

Abstract

The objective of this 8-week open-label study was to compare the tolerability of lercanidipine, a dihydropyridine calcium-channel antagonist (CA), with that of other CAs in the treatment of hypertension. Subjects already taking amlodipine, felodipine, nifedipine gastrointestinal therapeutic system (GITS), or nitrendipine and experiencing CA-specific adverse effects (AEs) were switched to lercanidipine for 4 weeks and then rechallenged with their initial treatment for 4 weeks. Results showed that at comparable levels of BP, lercanidipine was associated with a significantly lower incidence of ankle edema, flushing, rash, headache and dizziness compared with other CAs (p < 0.001). After 4 weeks of lercanidipine, mean systolic blood pressure (SBP)/diastolic blood pressure (DBP) was 142.1/86.7 mmHg. After rechallenge with other CAs for 4 weeks, mean SBP/DBP was 141.1/86.7 mmHg. In this open-label study, lercanidipine compared with other CA seems to provide a significant improvement in tolerability with comparable antihypertensive effect.

查看原文本刊更多论文

二氢吡啶钙通道拮抗剂莱卡尼地平耐受性的改善:莱卡尼地平挑战试验。

这项为期8周的开放标签研究的目的是比较雷卡尼地平(一种二氢吡啶钙通道拮抗剂(CA))与其他CA治疗高血压的耐受性。已经服用氨氯地平、非洛地平、硝苯地平胃肠道治疗系统(GITS)或尼群地平并出现ca特异性不良反应(ae)的受试者在4周后切换到雷卡尼地平，然后重新开始他们的初始治疗4周。结果显示，在同等血压水平下，与其他ca相比，来卡尼地平与踝关节水肿、潮红、皮疹、头痛和头晕的发生率显著降低相关(p < 0.001)。使用莱卡尼地平4周后，平均收缩压(SBP)/舒张压(DBP)为142.1/86.7 mmHg。再用其他ca治疗4周后，平均收缩压/舒张压为141.1/86.7 mmHg。在这项开放标签研究中，与其他CA相比，来卡尼地平似乎在耐受性方面有显著改善，并具有相当的降压效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood pressure. Supplement

自引率

0.00%

发文量